PDF herunterladen
Thromb Haemost 2019; 119(07): 1102-1111
DOI: 10.1055/s-0039-1687878
Cellular Haemostasis and Platelets
Georg Thieme Verlag KG Stuttgart · New York

Alteration in GPIIb/IIIa Binding of VWD-Associated von Willebrand Factor Variants with C-Terminal Missense Mutations

Gesa König
1   Department of Pediatric Hematology and Oncology, University Medical Center Hamburg-Eppendorf (UKE), University of Hamburg, Hamburg, Germany
,
Tobias Obser
1   Department of Pediatric Hematology and Oncology, University Medical Center Hamburg-Eppendorf (UKE), University of Hamburg, Hamburg, Germany
,
Olivier Marggraf
2   Center for Anesthesiology and Intensive Care Medicine, Department of Intensive Care Medicine, University Medical Center Hamburg-Eppendorf (UKE), University of Hamburg, Hamburg, Germany
,
Sonja Schneppenheim
3   Medilys Central Laboratory Coagulation, Asklepios Clinic Altona, Hamburg, Germany
,
Ulrich Budde
3   Medilys Central Laboratory Coagulation, Asklepios Clinic Altona, Hamburg, Germany
,
Reinhard Schneppenheim
1   Department of Pediatric Hematology and Oncology, University Medical Center Hamburg-Eppendorf (UKE), University of Hamburg, Hamburg, Germany
,
Maria A. Brehm
1   Department of Pediatric Hematology and Oncology, University Medical Center Hamburg-Eppendorf (UKE), University of Hamburg, Hamburg, Germany
› Institutsangaben Funding This study was supported by research funding from the German Research Foundation (DFG) to the Research Group FOR1543: “Shear flow regulation of hemostasis - bridging the gap between nanomechanics and clinical presentation.”
Weitere Informationen

Publikationsverlauf

08. November 2018

08. März 2019

Publikationsdatum:
29. April 2019 (online)

Auch verfügbar auf
    Lizenzen und Reprints

Abstract

The platelet receptor glycoprotein (GP) IIb/IIIa, formed by integrins αIIb and β3, plays an important role in platelet adhesion and aggregation. Its major binding site is the arginine-glycine-aspartic acid (RGD) sequence present in several adhesive proteins. Upon platelet activation, inside-out signaling activates the complex permitting binding to RGD motif containing proteins, such as von Willebrand factor (VWF). VWF is a large multidomain plasma GP essential to primary hemostasis, which can directly interact with platelets because it exhibits binding sites for GPIbα and GPIIb/IIIa in its A1 and C4 domain, respectively. A vast variety of VWF variants have been identified in which domain-specific mutations affect distinct functions of VWF but reduced GPIIb/IIIa binding has barely been studied so far. Here, we strived to investigate the influence of C domain mutations, which have been identified in patients diagnosed with von Willebrand disease (VWD), on VWF–GPIIb/IIIa interaction. To determine binding to membrane-incorporated GPIIb/IIIa in the absence of GPIbα, we developed and validated a cell-based binding assay which uses HEK293 cells stably expressing a constitutively active form of the GPIIb/IIIa receptor complex on their plasma membrane. By employing this assay, we measured GPIIb/IIIa binding of 14 VWF C domain mutants identified in VWD patients. Mutants p.Cys2257Arg, p.Gly2441Cys, p.Cys2477Tyr, and p.Pro2722Ala exhibited significantly reduced binding. Summarizing, we have developed a useful research tool to specifically investigate GPIIb/IIIa interaction with its protein binding partners and identified four VWF variants that exhibit impaired GPIIb/IIIa binding. At least in the homozygous state, this defect could contribute to the VWD phenotype.

Keywords

GPIIb/IIIa - αIIbβ3 - von Willebrand factor - von Willebrand disease

Supplementary Material

 

  • References

  • 1 Rauch A, Wohner N, Christophe OD, Denis CV, Susen S, Lenting PJ. On the versatility of von Willebrand factor. Mediterr J Hematol Infect Dis 2013; 5 (01) e2013046
    CrossrefPubMedGoogle Scholar
  • 2 Dejana E, Lampugnani MG, Giorgi M. , et al. Von Willebrand factor promotes endothelial cell adhesion via an Arg-Gly-Asp-dependent mechanism. J Cell Biol 1989; 109 (01) 367-375
    CrossrefPubMedGoogle Scholar
  • 3 Haverstick DM, Cowan JF, Yamada KM, Santoro SA. Inhibition of platelet adhesion to fibronectin, fibrinogen, and von Willebrand factor substrates by a synthetic tetrapeptide derived from the cell-binding domain of fibronectin. Blood 1985; 66 (04) 946-952
    CrossrefPubMedGoogle Scholar
  • 4 Mohri H, Fujimura Y, Shima M. , et al. Structure of the von Willebrand factor domain interacting with glycoprotein Ib. J Biol Chem 1988; 263 (34) 17901-17904
    CrossrefPubMedGoogle Scholar
  • 5 Plow EF, Srouji AH, Meyer D, Marguerie G, Ginsberg MH. Evidence that three adhesive proteins interact with a common recognition site on activated platelets. J Biol Chem 1984; 259 (09) 5388-5391
    CrossrefPubMedGoogle Scholar
  • 6 Vicente V, Kostel PJ, Ruggeri ZM. Isolation and functional characterization of the von Willebrand factor-binding domain located between residues His1-Arg293 of the alpha-chain of glycoprotein Ib. J Biol Chem 1988; 263 (34) 18473-18479
    CrossrefPubMedGoogle Scholar
  • 7 Sadler JE, Budde U, Eikenboom JC. , et al; Working Party on von Willebrand Disease Classification. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost 2006; 4 (10) 2103-2114
    CrossrefPubMedGoogle Scholar
  • 8 Schneppenheim R, Budde U. von Willebrand factor: the complex molecular genetics of a multidomain and multifunctional protein. J Thromb Haemost 2011; 9 (Suppl. 01) 209-215
    PubMedGoogle Scholar
  • 9 Abstracts of the XXV Congress of the International Society on Thrombosis and Haemostasis, June 20-25, 2015. J Thromb Haemost 2015; June 13 (Suppl. 02) 1-997
    PubMedGoogle Scholar
  • 10 Legendre P, Salsmann A, Rayes J, Trassard O, Kieffer N, Baruch D. CHO cells expressing the high affinity alpha(IIb)beta3 T562N integrin demonstrate enhanced adhesion under shear. J Thromb Haemost 2006; 4 (01) 236-246
    PubMedGoogle Scholar
  • 11 Goodeve A, Eikenboom J, Castaman G. , et al. Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand Disease (MCMDM-1VWD). Blood 2007; 109 (01) 112-121
    CrossrefPubMedGoogle Scholar
  • 12 Eikenboom J, Hilbert L, Ribba AS. , et al. Expression of 14 von Willebrand factor mutations identified in patients with type 1 von Willebrand disease from the MCMDM-1VWD study. J Thromb Haemost 2009; 7 (08) 1304-1312
    CrossrefPubMedGoogle Scholar
  • 13 Budde U, Schneppenheim R, Eikenboom J. , et al. Detailed von Willebrand factor multimer analysis in patients with von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 von Willebrand disease (MCMDM-1VWD). J Thromb Haemost 2008; 6 (05) 762-771
    CrossrefPubMedGoogle Scholar
  • 14 Marggraf O. Molekulargenetische Grundlage einer Variante des von Willebrand-Syndroms Typ 2. Univerity Hamburg; 2010
    Google Scholar
  • 15 Castaman G, Eikenboom JC, Lattuada A, Rodeghiero F. Grossly abnormal proteolysis of von Willebrand factor (VWF) in a patient heterozygous for a gene deletion and mutation in the dimerization area of VWF. Thromb Haemost 2000; 84 (04) 729-730
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 16 Eikenboom JC, Castaman G, Vos HL, Bertina RM, Rodeghiero F. Characterization of the genetic defects in recessive type 1 and type 3 von Willebrand disease patients of Italian origin. Thromb Haemost 1998; 79 (04) 709-717
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 17 Schneppenheim R, Castaman G, Federici AB. , et al. A common 253-kb deletion involving VWF and TMEM16B in German and Italian patients with severe von Willebrand disease type 3. J Thromb Haemost 2007; 5 (04) 722-728
    CrossrefPubMedGoogle Scholar
  • 18 Schneppenheim R, Michiels JJ, Obser T. , et al. A cluster of mutations in the D3 domain of von Willebrand factor correlates with a distinct subgroup of von Willebrand disease: type 2A/IIE. Blood 2010; 115 (23) 4894-4901
    CrossrefPubMedGoogle Scholar
  • 19 Schneppenheim R, Hellermann N, Brehm MA. , et al. The von Willebrand factor Tyr2561 allele is a gain-of-function variant and a risk factor for early myocardial infarction. Blood 2019; 133 (04) 356-365
    CrossrefPubMedGoogle Scholar
  • 20 Brehm MA, Huck V, Aponte-Santamaría C. , et al. von Willebrand disease type 2A phenotypes IIC, IID and IIE: a day in the life of shear-stressed mutant von Willebrand factor. Thromb Haemost 2014; 112 (01) 96-108
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 21 Mazurier C, Parquet-Gernez A, Goudemand M. Enzyme-linked immunoabsorbent assay of factor VIII-related antigen. Interest in study of Von Willebrand's disease (author's transl) [in French]. Pathol Biol (Paris) 1977; 25 (Suppl): 18-24
    PubMedGoogle Scholar
  • 22 Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat Methods 2012; 9 (07) 671-675
    CrossrefPubMedGoogle Scholar
  • 23 Steiner B, Cousot D, Trzeciak A, Gillessen D, Hadváry P. Ca2+-dependent binding of a synthetic Arg-Gly-Asp (RGD) peptide to a single site on the purified platelet glycoprotein IIb-IIIa complex. J Biol Chem 1989; 264 (22) 13102-13108
    CrossrefPubMedGoogle Scholar
  • 24 Rickham PP. Human experimentation. Code of ethics of the World Medical Association. Declaration of Helsinki. BMJ 1964; 2 (5402): 177
    CrossrefPubMedGoogle Scholar
  • 25 Kononova O, Litvinov RI, Blokhin DS. , et al. Mechanistic basis for the binding of RGD- and AGDV-peptides to the platelet integrin αIIbβ3. Biochemistry 2017; 56 (13) 1932-1942
    CrossrefPubMedGoogle Scholar
  • 26 Litvinov RI, Farrell DH, Weisel JW, Bennett JS. The platelet integrin αIIbβ3 differentially interacts with fibrin versus fibrinogen. J Biol Chem 2016; 291 (15) 7858-7867
    CrossrefPubMedGoogle Scholar
  • 27 Parise LV, Steiner B, Nannizzi L, Criss AB, Phillips DR. Evidence for novel binding sites on the platelet glycoprotein IIb and IIIa subunits and immobilized fibrinogen. Biochem J 1993; 289 (Pt 2): 445-451
    CrossrefPubMedGoogle Scholar
  • 28 Savage B, Shattil SJ, Ruggeri ZM. Modulation of platelet function through adhesion receptors. A dual role for glycoprotein IIb-IIIa (integrin alpha IIb beta 3) mediated by fibrinogen and glycoprotein Ib-von Willebrand factor. J Biol Chem 1992; 267 (16) 11300-11306
    CrossrefPubMedGoogle Scholar
  • 29 Parise LV, Phillips DR. Fibronectin-binding properties of the purified platelet glycoprotein IIb-IIIa complex. J Biol Chem 1986; 261 (30) 14011-14017
    CrossrefPubMedGoogle Scholar
  • 30 Mohri H, Ohkubo T. How vitronectin binds to activated glycoprotein IIb-IIIa complex and its function in platelet aggregation. Am J Clin Pathol 1991; 96 (05) 605-609
    CrossrefPubMedGoogle Scholar
  • 31 Xu ER, von Bulow S, Chen PC. , et al. Structure and dynamics of the platelet integrin-binding C4 domain of von Willebrand factor. Blood 2019; 133 (04) 366-376
    CrossrefPubMedGoogle Scholar